UniQure crashes as Huntington's gene therapy shows less slowing of disease at 4 years

UniQure's Huntington's disease gene therapy AMT-130 shows a reduced 44% slowing of disease progression at four years compared to the previously reported 75% at three years, causing its stock to fall nearly 40%. The FDA is reviewing UniQure's biologics license application amidst mixed efficacy data and manageable safety concerns.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.